Related Experiment Video
Updated: Aug 13, 2025
06:57
Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
Published on: June 14, 2019
10.5K
[Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests by the SPCPTGI]
Amélia Pedro1, Amália Pacheco2, Rita Sousa3
1Secção Portuguesa de Colposcopia e Patologia do Trato Genital Inferior da Sociedade Portuguesa de Ginecologia (SPCPTGI-SPG). Coimbra; Hospital CUF Sintra. Sintra. Portugal.
Acta Medica Portuguesa
|January 23, 2023
Summary
Updated cervical cancer screening guidelines are essential due to the human papillomavirus (HPV) test becoming the gold standard. These guidelines focus on risk stratification and management of abnormal screening results for improved secondary prevention.
Area of Science:
- Oncology
- Gynecology
- Public Health
Context:
- Cervical cancer remains a significant global health concern for women.
- Traditional screening methods are evolving with advancements in diagnostic testing.
- The human papillomavirus (HPV) test is now the gold standard for cervical cancer screening.
Purpose:
- To establish updated clinical practice guidelines for cervical cancer screening.
- To address the paradigm shift towards risk-stratified approaches.
- To provide recommendations for managing abnormal screening results.
Summary:
- Expert analysis of recent literature informed new clinical practice guidelines.
- Guidelines emphasize risk stratification, diagnostic evaluation, and therapeutic management.
- Focus on follow-up protocols for women with altered cervical cancer screening results.
Impact:
- Aims to guide clinical practice for improved management of abnormal screening results.
- Expected to enhance the secondary prevention of cervical cancer.
- Contributes to reducing the incidence of cervical cancer through optimized screening protocols.
